Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-05-27
2008-05-27
Wilson, Michael C. (Department: 1632)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S024100
Reexamination Certificate
active
07378244
ABSTRACT:
Telomerase reverse transcriptase is part of the telomerase complex responsible for maintaining telomere length and increasing the replicative capacity of progenitor cells. Telomerase activity is turned off in mature differentiated cells, but is turned back on again in hyperplastic diseases, including many cancers. This disclosure provides regulatory elements that promote transcription in cells that express telomerase reverse transcriptase (TERT). The disclosure also provides systems using TERT promoter sequences for identifying compounds that can be used to modulate telomerase expression.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4366241 (1982-12-01), Tom et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5416017 (1995-05-01), Burton et al.
patent: 5489508 (1996-02-01), West et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5728379 (1998-03-01), Martuza et al.
patent: 5747317 (1998-05-01), Cao
patent: 5770422 (1998-06-01), Collins
patent: 5907083 (1999-05-01), Robert et al.
patent: 5919656 (1999-07-01), Harrington et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6054575 (2000-04-01), Villeponteau et al.
patent: 6083717 (2000-07-01), Madzak et al.
patent: 6093809 (2000-07-01), Cech et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 6175060 (2001-01-01), Lefebvre et al.
patent: 6228643 (2001-05-01), Greenland et al.
patent: 6261556 (2001-07-01), Weinrich et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6271437 (2001-08-01), Jessen et al.
patent: 6274790 (2001-08-01), Kunst et al.
patent: 6281409 (2001-08-01), Woodhead et al.
patent: 6300095 (2001-10-01), Barredo Fuente et al.
patent: 6306656 (2001-10-01), Liu et al.
patent: 6331527 (2001-12-01), Parmacek et al.
patent: 6610839 (2003-08-01), Morin et al.
patent: 6627190 (2003-09-01), Wold et al.
patent: 6638762 (2003-10-01), Chang et al.
patent: 6686159 (2004-02-01), Andrews et al.
patent: 6777203 (2004-08-01), Morin et al.
patent: 6916642 (2005-07-01), Kilian et al.
patent: 7199234 (2007-04-01), Morin et al.
patent: 2003/0050264 (2003-03-01), Andrews et al.
patent: 2003/0096732 (2003-05-01), Andrews et al.
patent: 2003/0099616 (2003-05-01), Karpf et al.
patent: 2003/0104420 (2003-06-01), Andrews
patent: 2003/0113760 (2003-06-01), Andrews et al.
patent: 2003/0171326 (2003-09-01), Andrews et al.
patent: 2003/0211965 (2003-11-01), Andrews et al.
patent: 2004/0072787 (2004-04-01), Morin et al.
patent: 2005/0214923 (2005-09-01), DeChao et al.
patent: 2007/0190561 (2007-08-01), Morin et al.
patent: 2362367 (2000-08-01), None
patent: 1147181 (2004-12-01), None
patent: 2 317 891 (1998-04-01), None
patent: 2 321 642 (2000-02-01), None
patent: 09-154575 (1997-06-01), None
patent: WO 84/03564 (1984-09-01), None
patent: WO 95/13382 (1995-05-01), None
patent: WO 96/01835 (1996-01-01), None
patent: WO 96/12811 (1996-05-01), None
patent: WO 96/19580 (1996-06-01), None
patent: WO 96/40868 (1996-12-01), None
patent: WO 98/01542 (1998-01-01), None
patent: WO 98/01543 (1998-01-01), None
patent: WO 99/01560 (1998-01-01), None
patent: WO 98/07838 (1998-02-01), None
patent: WO 98/08938 (1998-03-01), None
patent: WO 98/14592 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/21343 (1998-05-01), None
patent: WO 98/37181 (1998-08-01), None
patent: WO 98/45450 (1998-10-01), None
patent: WO 98/59040 (1998-12-01), None
patent: WO 99/33998 (1999-07-01), None
patent: WO 99/38964 (1999-08-01), None
patent: WO 00/46355 (2000-08-01), None
patent: WO 01/23004 (2001-04-01), None
patent: WO 02/16657 (2002-02-01), None
patent: WO 02/16658 (2002-02-01), None
patent: WO 02/070668 (2002-09-01), None
patent: WO 02/072787 (2002-09-01), None
patent: WO 02/090570 (2002-11-01), None
patent: WO 02/090571 (2002-11-01), None
patent: WO 02/101010 (2002-12-01), None
patent: WO 03/000916 (2003-01-01), None
patent: WO 03/016474 (2003-02-01), None
Alemany, R., et al., Complementary adenoviral vectors for oncolysis, Cancer Gene Therapy 6:21 (1999).
Berenstein, M., et al., Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells, Cancer Gene Therapy 6:358 (1999).
Bi, W., et al., An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice, Cancer Gene Therapy 4:246 (1997).
Blackburn, R.V., et al., Adenoviral-mediated Transfer of Heat-inducible Double Suicide Gene into Prostate Carcinoma Cells, Cancer Res. 58:1358 (Apr. 1, 1998).
Bouali-Benazzouz, R., et al., Therapeutic efficacy of the thymidine kinase/ganciclovir system on large experimental gliomas: a nuclear magnetic resonance imaging study, Gene Therapy 6:1030 (1999).
Breakman, E., et al., Ganciclovir-mediated in vivo elimination of myeloid leukemic cells expressing the HSVtk gene induces HSVtk loss variants, Gene Therapy 6:1139 (1999).
Brand, K., et al., Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach, Gene Therapy 5:1363 (1998).
Cao, G., et al., Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter, Gene Therapy 6:83 (1999).
Chase, M., et al., An oncolytic viral mutant that delivers theCYP2B1transgene and augments cyclophosphamide chemotherapy, Nature Biotech. 16:444 (1998).
Chen, J., et al., Targeted In Vivo Delivery of Therapeutic Gene into Experimental Squamous Cell Carcinomas Using Anti-Epidermal Growth Factor Receptor Antibody: Immunogene Approach, Human Gene Therapy 9:2673 (1998).
Coffey, M.C., et al., Reovirus Therapy of Tumors with Activated Ras Pathway, Science 282:1332 (1998).
Delaney, C.L., et al., Conditional ablation of cerebellar astrocytes in postnatal transgenic mice, J. Neurosci. 16:6908 (1996).
Devereux, T.R., et al., DNA Methylation Analysis of the Promoter Region of the Human Telomerase Reverse Transcriptase (hTERT) Gene, Cancer Res. 59:6087 (1999).
Elshami, A.A., et al., The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo, Cancer Gene Therapy 4:213 (1997).
Greenberg, R.A., et al., Telomerase reverse transcriptase gene is a direct target of o-Myc but is not functionally equivalent in cellular transformation, Oncogene 18:1219(1999).
Hallenbeck, P.L., et al., A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma, Human Gene Therapy10:1721 (1999).
Heise, C.C., et al., Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intraturmoral spread and distribution effects, Cancer Gene Therapy 6:499 (1999).
Helse, C.C., et al., Intravenous Adminstration of ONYX-015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy, Cancer Res. 59:2623 (1999).
Harman, J.R., et al., In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical Trial, Human Gene Therapy 10:1239 (1999).
Heyman, R.A., et al., Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency, Proc. Natl. Acad. Sci. USA 86:2698 (1989).
Horikawa, I., et al., Cloning and Characterization of the Promoter Region ofHuman Telomerase Reverse TranscriptaseGene, Cancer Res. 59:826 (1999).
Kanai, F., et al., In Vivo Gene Therapy for α-Fetoprotein-producing Hepatocellular Carcinoma by Adenovirus-mediated Transfer of Cytosine Deaminase Gene, Cancer Res. 57:461 (1997).
Kasuya, H., et al., Intraperitoneal Delivery of hrR3 and Ganciclovir Prolongs Survival in Mice with Diss
Adams Robert
Andrews William H.
Lichtsteiner Serge
Morin Gregg B.
Vasserot Alain
Earp David J.
Geron Corporation
Mooi Leslie A.
Wilson Michael C.
LandOfFree
Telomerase promoters sequences for screening telomerase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Telomerase promoters sequences for screening telomerase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Telomerase promoters sequences for screening telomerase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2809314